Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Amgen, Inc.

Cancer Summaries and Commentaries®: Updates From Chicago on the Treatment of Lung Cancer

Release Date: October 15, 2021
Expiration Date: October 15, 2022

Activity Overview

This online activity is designed to update oncologists on data presented in 2021 on non-small cell lung cancer (NSCLC). This Cancer Summaries and Commentariesfacilitates the critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 5 reports on targeted and immunological therapy in NSCLC across the treatment continuum. For each report, a text-based summary of the background, study design, key results, and conclusions is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with lung cancer. Surgical oncologists, radiation oncologists, pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
  • Identify contemporary strategies in testing for predictive and prognostic biomarkers that guide decision-making in lung cancer management.
  • Assess recently reported safety and efficacy data applicable to the care of patients with lung cancer.
  • Place recent evidence from clinical trials in the context of evolving treatment paradigms in lung cancer care

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities


Jacob Sands, MD
Jacob Sands, MD
Dana-Farber Cancer Institute

Instructor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Daiichi-Sankyo, AstraZeneca, Takeda, Medtronic, Lilly, Jazz Pharmaceuticals, Blueprint Medicines

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By